Centre National De La Recherche Scientifique

Institut Curie

Institut National De La Sante Et De La Recherche Medicale

Universitè De Montpellier

Ab Science

Other

Université Pierre Et Marie Curie (paris Vi)

Université Montpellier 2 Sciences Et Techniques

Commissariat a L'energie Atomique

The University of British Columbia

Institute Curie

Centre for Drug Research and Development

The University of Montpellier 2 Science and Techniques

David Grierson

Jamal Tazi

Florence Mahuteau-Betzer

Emile R Bisagni

Pierre Roux

Abdellah Benjahad

Jean-Claude Florent

Alain Moussy

Claude Monneret

Ludger Johannes

Sylvie Robine

Jacky Roger

Chi Hung Nguyen

Martine Croisy

Philipe Maillard

Bruno Giethlen

Camille Georges Wermuth

Christian Rivalle

Anne-Marie Aubertin

Marco Ciufolini

Dominique Mabire

Fabrice Lejeune

Philippe Maillard

Andreï Popov

Valerie Dolle

Gérard Sanz

Johann Soret

Laurence Decrane

Val&eacute;rie Dolle

Chi Hung N'Guyen

Jérôme Guillemont

Danielle Carrez

Alain Croisy

Telmo Figueiredo

Bernard Loock

Philippe Jeanteur

Edith Mary Dullaghan

Alice Andree Valentine Devineau

Ronan Fb Gealageas

Edward Ewald Putnins

Camille Wermuth

Compounds and pharmaceutically acceptable salts thereof that may be used to treat a disease, for example, Duchenne muscular dystrophy, AIDS, and progeria. The compounds and pharmaceutically acceptable salts thereof may be part of a pharmaceutical composition including a pharmaceutically acceptable support.

Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies

Described herein are a series of compounds having the structure of Formula I: for use in the inhibition of MAO and uses thereof for the treatment of a barrier disease, obesity, solid epithelial cell tumor metastasis, diabetes, an auto-immune and inflammatory disease or a cardiometabolic disorder.

MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof

A method of treating a disease selected from the group consisting of cancer, Duchenne muscular dystrophy, AIDS, and progeria, that includes administering to a patient in need thereof an effective quantity of at least one compound of formula (IV) or a pharmaceutically acceptable salt thereof.

The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.

The present invention relates to a compound derived from indole corresponding to the following formula II: wherein X represents N, CR8 or NR8, wherein R8 represents a hydrogen atom, a hydroxyl or alkyl or methoxy group optionally substituted with a phenyl group; R2, R3 and R4 independently represent a hydrogen atom or a halogen atom or an optionally substituted alkyl, amine, alkene, ester, sulfonamide, ether or benzyl group; R5 represents a hydrogen atom or an optionally substituted, saturated or unsaturated alkyl group, amine, benzyl group; R6 represents an optionally substituted C1-C3 alkyl group; R7 represents a hydrogen atom or an optionally substituted C1-C3 alkyl group and R7 is absent when the ring A is in the b position, and A represents a ring; R9 and R10 represent together a carbon bond or independently represent an R11 OR11, SR11 group; wherein R11 represents a hydrogen atom, an optionally substituted, saturated or unsaturated, C1-C3 alkyl group, which may contain one or more sulfur, oxygen or nitrogen atoms; pharmaceutically acceptable salts of said compounds, their isomers and/or a mixture thereof; pharmaceutical composition comprising such a compound; the use of such a compound for preparing a drug intended to treat a genetic disease resulting from at least one mutation causing the occurrence of an early termination codon.

Compounds derived from indole and pharmaceutical compositions containing them

The present invention relates to novel compounds selected from substituted oxazole derivatives of formula (I) that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl and Flt-3 inhibitors.

Substituted oxazole derivatives and their use as tyrosine kinase inhibitors

The invention relates to new compounds for cancer therapy or diagnosis and more specifically to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gbreceptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein

[object Object]

The present invention relates to novel compounds selected from 2-aminoaryloxazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors.

2-aminoaryloxazole compounds as tyrosine kinase inhibitors

The invention relates to indole-derived compounds and to the use of said compounds for the preparation of a medicament that can be used to treat diseases related to the process of splicing pre-messenger RNAs in the cell, such as Frasier syndrome, frontotemporal dementia linked to chromosome 17 (a form of Parkinson's disease), Leigh syndrome (a type of encephalopathy), atypical cystic fibrosis, certain neuropathologies including Alzheimer's disease linked to a mutation in the Tau protein, muscle atorphy which affects the SMN (Survival of Motor Neuron) gene, depression linked to a serotonin splicing impairment, and certain cancers in which the global splicing process is affected (e.g. breast cancer, colon cancer and certain lymphomas), as well as viral diseases such as AIDS.

Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process

Shiga toxin B-subunit as a vector for tumor diagnosis and drug delivery to GB3 expressing tumors

The present invention concerns novel dibenzo[c,h][1,5]naphthyridine of formula (I) and their use as DNA probes, as well as the methods for marking DNA using the same. 

Dibenzo[c,h][1,5]naphthyridines and their use as DNA probes

The present invention relates to novel compounds selected from 2-aminoaryloxazoles of formula I that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors. 

The invention relates to new compounds for cancer therapy or diagnosis and to the use of a non-toxic B subunit of Shiga toxin mutant as a vector for diagnostic products or drugs in over-expressing Gb3 receptor cells, such compounds having the following formula: STxB-Z(n)-Cys-Y(m)-T wherein-STxB is the Shiga Toxin B subunit or a functional equivalent thereof, -Z(n) wherein n is 0 or 1, Z is an amino-acid residue devoid of sulfydryl groups, or is a polypeptide, -T is a molecule linked by a covalent bound to the S part of Cys, selected from: agents for in vivo diagnosis, cytotoxic agents, prodrugs, or enzymes for the conversion of a prodrug to a drug, - Y(m) wherein m is 0 or 1, Y is a linker between T and Cys, which is either cleavable or not cleavable for the release of T after the internalization of the hybrid compound into cells.

This invention relates to porphyrin compounds used to destroy or impair the functioning of a target biological material in photodynamic therapy, in particular against virus, tumoral cells, bacteria, tumorous tissues. The invention also relates to compositions containing such compounds and to a method in vitro to photosensitize detroy or impair the functioning of such target biological material.

Porphyrin derivatives for photodynamic therapy

Growing community of inventors

Versailles, France

David Grierson